
Sign up to save your podcasts
Or


Quick rundown of an important rheumatology RCT this week, discussing the IL-5 inhibitor benralizumab for the treatment of relapsing/refractory EGPA.
MANDARA Study: https://www.nejm.org/doi/full/10.1056/NEJMoa2311155
By Michael Putman4.9
114114 ratings
Quick rundown of an important rheumatology RCT this week, discussing the IL-5 inhibitor benralizumab for the treatment of relapsing/refractory EGPA.
MANDARA Study: https://www.nejm.org/doi/full/10.1056/NEJMoa2311155

503 Listeners

296 Listeners

129 Listeners

3,368 Listeners

1,147 Listeners

119 Listeners

194 Listeners

519 Listeners

67 Listeners

4 Listeners

375 Listeners

183 Listeners

186 Listeners

19 Listeners

6 Listeners